Overview
NICE is unable to make a recommendation on omaveloxolone (Skyclarys) for treating Friedreich’s ataxia in people 16 years and over. This is because Biogen withdrew its evidence submission.
Last reviewed: 06 May 2025
Next review: We will review this decision if the company decides to make a new submission.